Iverson Conrado Bezerra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iverson Conrado Bezerra has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Priscila Gubert
Keizo Asami Institute, iLIKA, Federal University of Pernambuco, Recife, Brazil
5 shared publications Artur José da Silva
Keizo Asami Institute, iLIKA, Federal University of Pernambuco, Recife, 50670-901, Brazil; Graduate Program in Biology Applied to Health, PPGBAS, Federal University of Pernambuco, Recife, 50670-901, Brazil
3 shared publicationsJosé Luiz de Lima Filho
Keizo Asami Institute, iLIKA, Federal University of Pernambuco, Recife, Brazil
3 shared publicationsJosivan Barbosa de Farias
Keizo Asami Institute, iLIKA, Federal University of Pernambuco, Recife, Brazil
2 shared publicationsRoberto Afonso da Silva
Keizo Asami Institute, iLIKA, Federal University of Pernambuco, Recife, Brazil
2 shared publicationsAna Cristina Gonçalves Reis de Melo
Environmental Chemistry Laboratory Center for Research and Graduate Studies in Science and Technology Federal University of Roraima (UFRR) Boa Vista RR Brazil
1 shared publication
Latest Publications
- Open Access
Label-Free Proteomics of α-Synuclein-Expressing Caenorhabditis elegans Model Uncovers Conserved Pathophysiological Pathways in Parkinson’s Disease
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease in the elderly population, characterized by a wide variety of motor and non-motor symptoms. Its complex biochemical and molecular mechanisms make it challenging to study PD directly in patients or to replicate it in vitro, underscoring the need for careful model characterization to advance translational research. The free-living nematode Caenorhabditis elegans has been widely used in neuroscience studies. Technological advancements enabled the development of transgenic strains that mimic aspects of neurodegenerative diseases, such as the OW13 strain [ grk-1 (ok1239) X; pkIs2386 IV ( unc-54 p::alpha-synuclein::YFP + unc-119 (+))], which expresses human α-synuclein in body wall muscle cells in a sensitized G-protein coupled receptor kinase-deficient background. This study conducted an exploratory proteomic analysis of the OW13 strain. A cross-species comparative analysis using post-mortem substantia nigra proteomics from PD individuals identified a convergent signature of 76 conserved C. elegans proteins, corresponding to 70 human orthologs, derived from the 373 DAPs. Among these conserved candidates, 68 proteins were upregulated, and 8 were downregulated. Functional enrichment linked these DAPs to the tricarboxylic acid cycle, mitochondrial function, and protein quality control, suggesting that α-synuclein aggregation triggers a broad proteostatic and bioenergetic remodeling resembling PD pathophysiology. This first proteomic and cross-species characterization of the OW13 strain strongly supports C. elegans as a robust PD model.
Open AccessLabel-Free Proteomics of α-Synuclein-Expressing Caenorhabditis elegans Model Uncovers Conserved Pathophysiological Pathways in Parkinson’s Disease
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease in the elderly population, characterized by a wide variety of motor and non-motor symptoms. Its complex biochemical and molecular mechanisms make it challenging to study PD directly in patients or to replicate it in vitro, underscoring the need for careful model characterization to advance translational research. The free-living nematode Caenorhabditis elegans has been widely used in neuroscience studies. Technological advancements enabled the development of transgenic strains that mimic aspects of neurodegenerative diseases, such as the OW13 strain [ grk-1 (ok1239) X; pkIs2386 IV ( unc-54 p::alpha-synuclein::YFP + unc-119 (+))], which expresses human α-synuclein in body wall muscle cells in a sensitized G-protein coupled receptor kinase-deficient background. This study conducted an exploratory proteomic analysis of the OW13 strain. A cross-species comparative analysis using post-mortem substantia nigra proteomics from PD individuals identified a convergent signature of 76 conserved C. elegans proteins, corresponding to 70 human orthologs, derived from the 373 DAPs. Among these conserved candidates, 68 proteins were upregulated, and 8 were downregulated. Functional enrichment linked these DAPs to the tricarboxylic acid cycle, mitochondrial function, and protein quality control, suggesting that α-synuclein aggregation triggers a broad proteostatic and bioenergetic remodeling resembling PD pathophysiology. This first proteomic and cross-species characterization of the OW13 strain strongly supports C. elegans as a robust PD model.
- 27 December 2025
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 143, 109268
Computational insights into terpene-induced modulation of amyloid-β peptide (Aβ1–42) aggregation-favoring conformations
- 27 December 2025
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 143, 109268
Computational insights into terpene-induced modulation of amyloid-β peptide (Aβ1–42) aggregation-favoring conformations
- Open Access
- 13 July 2025
- Published by Wiley in Journal of Neurochemistry
- Vol. 169 (7) , e70152
Label‐Free Proteomic Profiling of the dvls2 (CL2006) Caenorhabditis elegans Alzheimer's Disease (AD) Model Reveals Conserved Molecular Signatures Shared With the Human AD Brain
Alzheimer's disease (AD) is the most common form of dementia, posing significant challenges to cognitive, emotional, social, and financial well‐being. The biochemical and molecular pathways associated with AD are complex, making it difficult to study and simulate in patients or through in vitro research. Thus, animal models play a crucial role in investigating the development and progression of AD. One widely used model in neuroscience studies is the free‐living nematode Caenorhabditis elegans (C. elegans). The development of transgenic animals has allowed for the construction of the dvls2 (CL2006) C. elegans strain, which constitutively expresses the amyloid beta (Aβ) peptide. This study conducted a proteomic analysis on the dvls2 (CL2006) strain. Also, a cross‐species comparative analysis was performed using microarray data from AD patients to identify genes with ontology in the dvls2 (CL2006). A total of 543 proteins were found to be differentially regulated in the dvls2 (CL2006) strain. Furthermore, in the analysis of the human datasets, 397 upregulated and 767 downregulated genes were identified. The differentially expressed genes (DEGs) were analyzed in Ortholist to identify their orthologs in C. elegans. Then, the orthologous genes in the dvls2 (CL2006) model were compared to the proteomic data, resulting in the identification of 29 upregulated and 24 downregulated proteins (DEPs). Functional enrichment analysis of DEPs revealed terms related to pyruvate, glucose, and glutamate metabolism, in addition to binding activities to unfolded proteins and ligases, highlighting the upregulation of chaperone and ubiquitination‐associated proteins. Protein–protein network (PPI) was performed for the human DEGs and DEPs of dvls2 (CL2006). Topological analyses of the networks were performed, revealing the following C. elegans hub proteins: EEF‐2, ALH‐13, ENOL‐1, RPL‐2, TPI‐1, CTS‐1, RPL‐9, RPL‐23, CCT‐1, and RPS‐8. eEF‐2 was identified as a key regulator of the human AD PPI and dvls2 (CL2006). Modules were analyzed in the networks, and the presence of key regulators was identified. This study provides the first proteomic characterization of the AD model dvls2 (CL2006) and a cross‐species comparative analysis with data from AD individuals, supporting the use of dvls2 (CL2006) in AD studies. image
- 13 July 2025
- Published by Wiley in Journal of Neurochemistry
- Vol. 169 (7) , e70152
Open AccessLabel‐Free Proteomic Profiling of the dvls2 (CL2006) Caenorhabditis elegans Alzheimer's Disease (AD) Model Reveals Conserved Molecular Signatures Shared With the Human AD Brain
Alzheimer's disease (AD) is the most common form of dementia, posing significant challenges to cognitive, emotional, social, and financial well‐being. The biochemical and molecular pathways associated with AD are complex, making it difficult to study and simulate in patients or through in vitro research. Thus, animal models play a crucial role in investigating the development and progression of AD. One widely used model in neuroscience studies is the free‐living nematode Caenorhabditis elegans (C. elegans). The development of transgenic animals has allowed for the construction of the dvls2 (CL2006) C. elegans strain, which constitutively expresses the amyloid beta (Aβ) peptide. This study conducted a proteomic analysis on the dvls2 (CL2006) strain. Also, a cross‐species comparative analysis was performed using microarray data from AD patients to identify genes with ontology in the dvls2 (CL2006). A total of 543 proteins were found to be differentially regulated in the dvls2 (CL2006) strain. Furthermore, in the analysis of the human datasets, 397 upregulated and 767 downregulated genes were identified. The differentially expressed genes (DEGs) were analyzed in Ortholist to identify their orthologs in C. elegans. Then, the orthologous genes in the dvls2 (CL2006) model were compared to the proteomic data, resulting in the identification of 29 upregulated and 24 downregulated proteins (DEPs). Functional enrichment analysis of DEPs revealed terms related to pyruvate, glucose, and glutamate metabolism, in addition to binding activities to unfolded proteins and ligases, highlighting the upregulation of chaperone and ubiquitination‐associated proteins. Protein–protein network (PPI) was performed for the human DEGs and DEPs of dvls2 (CL2006). Topological analyses of the networks were performed, revealing the following C. elegans hub proteins: EEF‐2, ALH‐13, ENOL‐1, RPL‐2, TPI‐1, CTS‐1, RPL‐9, RPL‐23, CCT‐1, and RPS‐8. eEF‐2 was identified as a key regulator of the human AD PPI and dvls2 (CL2006). Modules were analyzed in the networks, and the presence of key regulators was identified. This study provides the first proteomic characterization of the AD model dvls2 (CL2006) and a cross‐species comparative analysis with data from AD individuals, supporting the use of dvls2 (CL2006) in AD studies. image
- 1 November 2024
- Published by Bentham Science Publishers Ltd. in The Natural Products Journal
- Vol. 14 (8) , 1-14
Caenorhabditis elegans as an Outstanding Model to Explore Flavonoids Under Stress Conditions
Plants produce promising chemicals called secondary metabolites in response to stress, which protect against oxidative damage in both plants and humans. Reactive oxygen species (ROS) levels combined with an imbalance in the antioxidant responses can trigger oxidative stress that is related to many conditions such as Alzheimer's disease, diabetes, and cancer. One way to counteract or avoid the stress excess is by flavonoid administration, a class of plant metabolites with a consistent antioxidant action and the ability to inactivate the free radical excess. The mechanisms, as well as the benefits and toxicity of antioxidant products, can be tested in alternative animal models. The mechanisms, as well as the benefits and toxicity of antioxidant products, can be tested in alternative animal models. In this review, we explored how Caenorhabditis elegans, a nematode with high genetic similarity to human genes and the antioxidant response pathway conserved, can be considered an attractive model organism for testing flavonoid compounds. Here, we emphasize the crucial results regarding C. elegans and the flavonoid quercetin, focusing on oxidative stress and aging investigations. Also, this review highlights the quercetin benefits in C. elegans lifespan, healthspan, neurodegeneration, and impacts on insulin/IGF-1 signaling (IIS).
- 1 November 2024
- Published by Bentham Science Publishers Ltd. in The Natural Products Journal
- Vol. 14 (8) , 1-14
Caenorhabditis elegans as an Outstanding Model to Explore Flavonoids Under Stress Conditions
Plants produce promising chemicals called secondary metabolites in response to stress, which protect against oxidative damage in both plants and humans. Reactive oxygen species (ROS) levels combined with an imbalance in the antioxidant responses can trigger oxidative stress that is related to many conditions such as Alzheimer's disease, diabetes, and cancer. One way to counteract or avoid the stress excess is by flavonoid administration, a class of plant metabolites with a consistent antioxidant action and the ability to inactivate the free radical excess. The mechanisms, as well as the benefits and toxicity of antioxidant products, can be tested in alternative animal models. The mechanisms, as well as the benefits and toxicity of antioxidant products, can be tested in alternative animal models. In this review, we explored how Caenorhabditis elegans, a nematode with high genetic similarity to human genes and the antioxidant response pathway conserved, can be considered an attractive model organism for testing flavonoid compounds. Here, we emphasize the crucial results regarding C. elegans and the flavonoid quercetin, focusing on oxidative stress and aging investigations. Also, this review highlights the quercetin benefits in C. elegans lifespan, healthspan, neurodegeneration, and impacts on insulin/IGF-1 signaling (IIS).
- 22 January 2024
- Published by Wiley in Chemistry & Biodiversity
- Vol. 21 (2) , e202301536
In Vitro and In Silico Antioxidant Activity and Molecular Characterization of Bauhinia ungulata L. Essential Oil
Bauhinia ungulata is an antioxidant medicinal plant that has been manipuled in Brazil to lower glycemic index as well is for alternative treatment for diabetes. Therefore, the present hearch has aimed to investigates the antioxidant effects of the essential oil of Bauhinia ungulata L. (EOBU) collected in Amazon region better specified in Boa Vista, Roraima, Brazil, located in the Amazon region. Gas chromatography had been used to characterize the components, and antioxidant assays such as DPPH, TAC, reducing power, Fe2+ chelation, and total phenols had also been performed. The major constituents had molecularly anchored with the human catalase (CAT) enzyme, and maltol has showed as a positive control. Among the 25 revealed components, the main ones have been α‐bisabolol (27.2 %), β‐Caryophyllene (12.5 %) and Epi‐γ‐eudesmol (13.6 %). The EOBU has comproved a TAC value of 618.79 mg of ascorbic acid equivalent, free radical scavenging capacity (DPPH) around 53.7 % and 65.27 %, Fe2+ chelation capacity of 161±6 and 126.7±39.6, for 0.1 mg.mL−1 and 0.5 mg.mL−1, respectively. The power around the EOBU has appeared percentages equals to 28.66 %, 44.6 %, and 77.03 % in the concentrations tested. As well as, 96.5 % of total phenols. The compounds α‐bisabolol (−5.7±0.4 Kcal.mol−1) and β‐caryophyllene (−6.1±0.5 Kcal.mol−1) have showed good interaction with CAT compared to Maltol (−4.4±0.4 Kcal.mol−1). The present work has demonstrated that EOBU functions as a potent antioxidant, capable of scavenging free radicals and reducing oxidative stress damage.
- 22 January 2024
- Published by Wiley in Chemistry & Biodiversity
- Vol. 21 (2) , e202301536
In Vitro and In Silico Antioxidant Activity and Molecular Characterization of Bauhinia ungulata L. Essential Oil
Bauhinia ungulata is an antioxidant medicinal plant that has been manipuled in Brazil to lower glycemic index as well is for alternative treatment for diabetes. Therefore, the present hearch has aimed to investigates the antioxidant effects of the essential oil of Bauhinia ungulata L. (EOBU) collected in Amazon region better specified in Boa Vista, Roraima, Brazil, located in the Amazon region. Gas chromatography had been used to characterize the components, and antioxidant assays such as DPPH, TAC, reducing power, Fe2+ chelation, and total phenols had also been performed. The major constituents had molecularly anchored with the human catalase (CAT) enzyme, and maltol has showed as a positive control. Among the 25 revealed components, the main ones have been α‐bisabolol (27.2 %), β‐Caryophyllene (12.5 %) and Epi‐γ‐eudesmol (13.6 %). The EOBU has comproved a TAC value of 618.79 mg of ascorbic acid equivalent, free radical scavenging capacity (DPPH) around 53.7 % and 65.27 %, Fe2+ chelation capacity of 161±6 and 126.7±39.6, for 0.1 mg.mL−1 and 0.5 mg.mL−1, respectively. The power around the EOBU has appeared percentages equals to 28.66 %, 44.6 %, and 77.03 % in the concentrations tested. As well as, 96.5 % of total phenols. The compounds α‐bisabolol (−5.7±0.4 Kcal.mol−1) and β‐caryophyllene (−6.1±0.5 Kcal.mol−1) have showed good interaction with CAT compared to Maltol (−4.4±0.4 Kcal.mol−1). The present work has demonstrated that EOBU functions as a potent antioxidant, capable of scavenging free radicals and reducing oxidative stress damage.